Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Colchicine in STEMI Patients
NCT06054100Phase 3Completed
- Sponsor
- Ain Shams University
- Start
- Feb 2020
- Primary completion
- Feb 2022
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of colchicine in ST elevation myocardial infarction (STEMI) (2 arms), sponsored by Ain Shams University. Primary endpoint: Soluble Suppression of Tumorigenicity 2 at 3 months. Started Feb 2020; status: completed.
02
Drugs
colchicine
03
Conditions
ST elevation myocardial infarction (STEMI)
Beyond the preview
Go deeper on NCT06054100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06054100.